RU2017132275A - Способ измерения изменения в иммунном репертуаре индивидуума - Google Patents
Способ измерения изменения в иммунном репертуаре индивидуума Download PDFInfo
- Publication number
- RU2017132275A RU2017132275A RU2017132275A RU2017132275A RU2017132275A RU 2017132275 A RU2017132275 A RU 2017132275A RU 2017132275 A RU2017132275 A RU 2017132275A RU 2017132275 A RU2017132275 A RU 2017132275A RU 2017132275 A RU2017132275 A RU 2017132275A
- Authority
- RU
- Russia
- Prior art keywords
- sample
- subject
- frequency
- amplicons
- clonotypes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Analytical Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
Claims (31)
1. Способ расчета изменения в иммунном репертуаре субъекта, включающий стадии
количественного измерения клонотипов иммунных клеток в популяции или субпопуляции иммунных клеток в первом образце и втором образце, забранных у одного пациента;
расчета данных по частоте для первого образца и второго образца посредством идентификации частоты каждого клонотипа;
нормирования данных по частоте для первого образца и второго образца;
определения абсолютного различия в частоте каждого клонотипа, присутствующего в первом образце и втором образце; и
определения общих клонотипов для первого образца и второго образца с наибольшим изменением частоты.
2. Способ по п. 1, в котором клонотипы иммунных клеток количественно измеряют с использованием arm-ПЦР и секвенирования следующего поколения.
3. Способ по п. 1, в котором клонотипы представляют собой клонотипы CDR3.
4. Способ по п. 1, в котором первый образец и второй образец забирают в один и тот же момент времени.
5. Способ по п. 1, в котором первый образец и второй образец забирают в разные моменты времени.
6. Способ по п. 1, в котором идентифицируют по меньшей мере 100 клонотипов с наибольшим изменением частоты.
7. Способ по п. 1, в котором каждый образец содержит лейкоциты.
8. Способ по п. 1, в котором субъект является здоровым.
9. Способ по п. 1, в котором у субъекта было диагностировано или подозревается наличие заболевания.
10. Способ по п. 1, в котором субъекта лечат иммунотерапией.
11. Способ по п. 10, в котором субъект получает иммунотерапию после забора первого образца.
12. Способ расчета изменения в иммунном репертуаре субъекта, включающий стадии
забора по меньшей мере двух образцов популяций лейкоцитов от субъекта;
амплификации по отдельности полинуклеотидов из каждой популяции лейкоцитов в реакционной смеси, содержащей специфичные к мишени вложенные праймеры для получения набора первых ампликонов, по меньшей мере часть специфичных к мишени вложенных праймеров, содержащих дополнительные нуклеотиды, которые, на протяжении амплификации, служат в качестве матрицы для включения в первые ампликоны сайта связывания для по меньшей мере одного общего праймера;
переноса по отдельности части каждой из первых реакционных смесей, содержащей первые ампликоны, во вторые реакционные смеси, содержащие по меньшей мере один общий праймер;
амплификации для каждой популяции с использованием по меньшей мере одного общего праймера, первых ампликонов с получением набора вторых ампликонов;
секвенирования каждого из вторых ампликонов для идентификации частоты специфических областей CDR3, присутствующих в образце;
нормирования данных по частоте CDR3;
сравнения нормированных данных по частоте CDR3 первого образца и второго образца для определения абсолютного различия между частотой каждой последовательности CDR3; и
определения общих последовательностей CDR3 для первого образца и второго образца с наибольшими изменениями частоты.
13. Способ по п. 12, в котором первый образец и второй образец забирают в один и тот же момент времени.
14. Способ по п. 12, в котором первый образец и второй образец забирают в разные моменты времени.
15. Способ по п. 12, в котором субъект является здоровым.
16. Способ по п. 12, в котором у субъекта было диагностировано или подозревается наличие заболевания.
17. Способ по п. 1, в котором субъекта лечат иммунотерапией.
18. Способ по п. 10, в котором субъект получает иммунотерапию после забора первого образца.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129706P | 2015-03-06 | 2015-03-06 | |
| US62/129,706 | 2015-03-06 | ||
| PCT/US2016/020939 WO2016144776A1 (en) | 2015-03-06 | 2016-03-04 | Method for measuring a change in an individual's immunorepertoire |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017132275A3 RU2017132275A3 (ru) | 2019-04-08 |
| RU2017132275A true RU2017132275A (ru) | 2019-04-08 |
| RU2714752C2 RU2714752C2 (ru) | 2020-02-19 |
Family
ID=56849672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017132275A RU2714752C2 (ru) | 2015-03-06 | 2016-03-04 | Способ измерения изменения в иммунном репертуаре индивидуума |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10529442B2 (ru) |
| EP (1) | EP3265591A4 (ru) |
| JP (1) | JP6974181B2 (ru) |
| KR (1) | KR20170134432A (ru) |
| CN (2) | CN115449542A (ru) |
| AU (2) | AU2016229162A1 (ru) |
| BR (1) | BR112017019148A2 (ru) |
| CA (1) | CA2978751A1 (ru) |
| HK (1) | HK1245848A1 (ru) |
| RU (1) | RU2714752C2 (ru) |
| SG (1) | SG11201707045YA (ru) |
| WO (1) | WO2016144776A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012037524A2 (en) | 2010-09-16 | 2012-03-22 | The General Hospital Corporation | Red blood cell dynamics for diagnosis |
| US11293852B2 (en) * | 2016-04-07 | 2022-04-05 | The General Hospital Corporation | White blood cell population dynamics |
| US20200199650A1 (en) * | 2017-05-18 | 2020-06-25 | Geneplus－Beijing | Analysis system for peripheral blood-based non-invasive detection of lesion immune repertoire diversity and uses of system |
| CN111383736A (zh) * | 2018-12-28 | 2020-07-07 | 康多富国际有限公司 | 免疫系统疾病保健食品组合确定方法及其可读取储存媒体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009231582B2 (en) * | 2008-04-03 | 2015-02-26 | iRepertoire, Inc. | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
| US9012148B2 (en) * | 2008-04-16 | 2015-04-21 | Jian Han | Method for evaluating and comparing immunorepertoires |
| US9234240B2 (en) * | 2010-05-07 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| US20120183969A1 (en) * | 2011-01-14 | 2012-07-19 | Jian Han | Immunodiversity Assessment Method and Its Use |
| US20140356339A1 (en) * | 2011-09-09 | 2014-12-04 | Sequenta Inc. | Sequence-based measures of immune response |
| WO2014008448A1 (en) * | 2012-07-03 | 2014-01-09 | Sloan Kettering Institute For Cancer Research | Quantitative assessment of human t-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation |
| US20140065629A1 (en) * | 2012-08-29 | 2014-03-06 | Israel Barken | Methods of treating diseases |
| US9909180B2 (en) * | 2013-02-04 | 2018-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| US20160034637A1 (en) | 2013-02-11 | 2016-02-04 | Cb Biotechnologies, Inc. | Method for evaluating an immunorepertoire |
| US20160169890A1 (en) * | 2013-05-20 | 2016-06-16 | The Trustees Of Columbia University In The City Of New York | Tracking donor-reactive tcr as a biomarker in transplantation |
| WO2016086029A1 (en) * | 2014-11-25 | 2016-06-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
-
2016
- 2016-03-04 WO PCT/US2016/020939 patent/WO2016144776A1/en active Application Filing
- 2016-03-04 CN CN202210692616.4A patent/CN115449542A/zh active Pending
- 2016-03-04 EP EP16762225.7A patent/EP3265591A4/en active Pending
- 2016-03-04 AU AU2016229162A patent/AU2016229162A1/en not_active Abandoned
- 2016-03-04 KR KR1020177027829A patent/KR20170134432A/ko not_active Application Discontinuation
- 2016-03-04 RU RU2017132275A patent/RU2714752C2/ru active
- 2016-03-04 CA CA2978751A patent/CA2978751A1/en active Pending
- 2016-03-04 JP JP2017564771A patent/JP6974181B2/ja active Active
- 2016-03-04 BR BR112017019148A patent/BR112017019148A2/pt not_active Application Discontinuation
- 2016-03-04 CN CN201680013959.6A patent/CN107429293A/zh active Pending
- 2016-03-04 SG SG11201707045YA patent/SG11201707045YA/en unknown
- 2016-03-04 US US15/060,992 patent/US10529442B2/en active Active
-
2018
- 2018-04-19 HK HK18105121.1A patent/HK1245848A1/zh unknown
-
2022
- 2022-04-19 AU AU2022202555A patent/AU2022202555A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10529442B2 (en) | 2020-01-07 |
| HK1245848A1 (zh) | 2018-08-31 |
| EP3265591A1 (en) | 2018-01-10 |
| WO2016144776A1 (en) | 2016-09-15 |
| RU2714752C2 (ru) | 2020-02-19 |
| CN115449542A (zh) | 2022-12-09 |
| CA2978751A1 (en) | 2016-09-15 |
| RU2017132275A3 (ru) | 2019-04-08 |
| EP3265591A4 (en) | 2019-04-10 |
| CN107429293A (zh) | 2017-12-01 |
| US20160259884A1 (en) | 2016-09-08 |
| KR20170134432A (ko) | 2017-12-06 |
| AU2016229162A1 (en) | 2017-09-21 |
| AU2022202555A1 (en) | 2022-05-12 |
| SG11201707045YA (en) | 2017-09-28 |
| JP6974181B2 (ja) | 2021-12-01 |
| JP2018506996A (ja) | 2018-03-15 |
| BR112017019148A2 (pt) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018138508A (ru) | Способы выявления рака легкого | |
| Bustin | Why the need for qPCR publication guidelines?—The case for MIQE | |
| van Vliet et al. | Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs | |
| RU2017132275A (ru) | Способ измерения изменения в иммунном репертуаре индивидуума | |
| JP2019527544A (ja) | 分子マーカー、参照遺伝子、及びその応用、検出キット、並びに検出モデルの構築方法 | |
| RU2014120427A (ru) | Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака | |
| WO2015134787A2 (en) | Methods using randomer-containing synthetic molecules | |
| WO2010139812A4 (en) | miRNA FINGERPRINT IN THE DIAGNOSIS OF DISEASES | |
| CN103958695A (zh) | 一种通过检测生物液体中miRNA来鉴定患早期肺癌的无症状高风险个体的方法 | |
| Pisapia et al. | Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021 | |
| US20170088895A1 (en) | Immunorepertoire normality assessment method and its use | |
| JPWO2014003053A1 (ja) | 膵臓がんの検出方法及び検出用キット | |
| JP2017184642A (ja) | 認知症マーカー、それを用いた認知症の評価方法、評価試薬および評価キット | |
| JP2018531044A6 (ja) | 免疫レパートリーの正常性の評価方法およびその使用 | |
| Liu et al. | Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study | |
| WO2018097614A2 (ko) | 유방암 환자의 화학치료 유용성 예측 방법 | |
| JP2018512160A5 (ru) | ||
| CN108884492A (zh) | 借助多中心mirna谱的阿尔茨海默病中的特定标记 | |
| KR101828125B1 (ko) | 다발성 경화증에서의 진단 miRNA 프로파일 | |
| CN104694623A (zh) | 一种用于肺癌诊断的血浆miRNA标志物及应用 | |
| RU2016100626A (ru) | Способ прогнозирования тяжести течения и исхода заболевания у пациентов с хирургическим сепсисом | |
| CN107988370A (zh) | 一种circRNA基因在制备诊断慢性粒细胞性白血病试剂中的应用 | |
| JP2014502491A (ja) | 形質細胞疾患 | |
| CN103923981B (zh) | Hla-b*27等位基因检测方法及其试剂盒 | |
| RU2017132290A (ru) | Способ идентификации в иммунном репертуаре cdr3 участков, ассоциированных с заболеваниями |